Melphalan Sun (Melphalan)

Melphalan belongs to the alkylating agent class. It binds covalently to DNA, creating cross‑links that prevent DNA replication and transcription. This disruption triggers programmed cell death, particularly in rapidly dividing cancer cells, without requiring a specific receptor target.

The exact dose of Melphalan Sun is individualized. A qualified prescriber determines the amount, frequency and duration based on the patient’s diagnosis, body surface area, renal function and overall treatment plan.

Melphalan is classified as potentially teratogenic, and its safety in pregnancy has not been established. It is generally avoided in pregnant patients, and breastfeeding is not recommended while receiving treatment due to possible drug transfer to the infant.

To request Melphalan Sun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Melphalan is similar to other alkylating agents such as cyclophosphamide but differs in its potency and spectrum of activity. It tends to have a higher myelosuppressive profile and is often chosen for specific indications like multiple myeloma, whereas cyclophosphamide is used more broadly in various solid‑tumor protocols.

Melphalan Sun should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and light, and avoid freezing. Follow standard aseptic handling procedures when preparing for intra‑arterial or intravenous administration.

Melphalan Sun is supplied as a sterile solution for injection and is administered by a healthcare professional via intra‑arterial or intravenous infusion. The infusion rate and duration are set by the treating physician according to the prescribed regimen.

The most serious risks include severe myelosuppression leading to infection or bleeding, secondary malignancies, pulmonary toxicity such as interstitial pneumonitis, and renal impairment. Patients should be closely monitored for signs of infection, respiratory distress and changes in kidney function.

Melphalan Sun is contraindicated in patients with known hypersensitivity to melphalan or other alkylating agents, in pregnant women, and in individuals with severe bone‑marrow failure or uncontrolled renal dysfunction. Caution is also advised for patients receiving other myelosuppressive therapies.